Table 5. Univariate analysis results of uric acid levels by group.
| Variable | Normal group (n=118) | Abnormal group (n=10) | Univariate | |
|---|---|---|---|---|
| HR (95% CI) | p-value | |||
| Age (yr) | 42.04±15.23 | 37.00±8.11 | 0.974 (0.930~1.017) | 0.252 |
| Sex† | ||||
| Male | 61 (51.7) | 10 (100.0) | 0.048 (0~0.372) | 0.046* |
| Female | 57 (48.3) | 0 (0.0) | ||
| BMI (kg/m2)† | 24.11±3.92 | 25.68±4.60 | 1.107 (0.903~1.348) | 0.311 |
| Duration of disease (mo) | 95.56±106.91 | 93.90±78.07 | 1 (0.993~1.005) | 0.891 |
| PASI score§ | ||||
| ≤10 | 41 (40.2) | 2 (20.0) | 1.022 (0.962~1.075) | 0.440 |
| >10 | 61 (59.8) | 8 (80.0) | ||
| Total medication period (d) | 320.67±348.75 | 369.10±179.33 | 0.999 (0.995~1.001) | 0.324 |
| Cumulative dose (g) | 44.85±44.34 | 56.81±26.61 | 1 (1~1) | 0.464 |
| Underlying diseases | ||||
| Diabetes | 7 (5.9) | 1 (10.0) | 0.671 (0.125~12.403) | 0.706 |
| Hypertension | 13 (11.0) | 1 (10.0) | 1.240 (0.231~22.937) | 0.839 |
| Dyslipidemia† | 9 (7.6) | 0 (0.0) | 2.075 (0.265~267.712) | 0.632 |
| Chronic hepatitis B infection† | 3 (2.5) | 0 (0.0) | 0.770 (0.097~99.639) | 0.865 |
| Kidney disease† | 1 (0.8) | 0 (0.0) | 0.108 (0.013~14.064) | 0.160 |
| Others∥ | 8 (6.8) | 1 (10.0) | 0.639 (0.120~11.795) | 0.671 |
Values are presented as mean±standard deviation or number (%). BMI: body mass index, PASI: psoriasis area and severity index, HR: hazard ratio, CI: confidence interval. *p<0.05. †Firth's correction was applied. ‡Including only patients for whom BMI (total=57, normal=51, abnormal=6) was available. §Including only patients for whom PASI score (total=112, normal=102, abnormal=10) was available. ∥Angina, aortic dissection, autism, brain hemorrhage, stroke, thyroid disease.